Source: Frontiers in Pharmacology. Unidade: FMRP
Subjects: CANABINOIDES, ANSIOLÍTICOS
ABNT
RUGGIERO, Rafael N. et al. Cannabinoids and vanilloids in schizophrenia: neurophysiological evidence and directions for basic research. Frontiers in Pharmacology, v. 8, 2017Tradução . . Disponível em: https://doi.org/10.3389/fphar.2017.00399. Acesso em: 09 maio 2024.APA
Ruggiero, R. N., Rossignoli, M. T., De Ross, J. B., & Hallak, J. E. C. (2017). Cannabinoids and vanilloids in schizophrenia: neurophysiological evidence and directions for basic research. Frontiers in Pharmacology, 8. doi:10.3389/fphar.2017.00399NLM
Ruggiero RN, Rossignoli MT, De Ross JB, Hallak JEC. Cannabinoids and vanilloids in schizophrenia: neurophysiological evidence and directions for basic research [Internet]. Frontiers in Pharmacology. 2017 ; 8[citado 2024 maio 09 ] Available from: https://doi.org/10.3389/fphar.2017.00399Vancouver
Ruggiero RN, Rossignoli MT, De Ross JB, Hallak JEC. Cannabinoids and vanilloids in schizophrenia: neurophysiological evidence and directions for basic research [Internet]. Frontiers in Pharmacology. 2017 ; 8[citado 2024 maio 09 ] Available from: https://doi.org/10.3389/fphar.2017.00399